



Minomic International Ltd

Up to \$2M Equity Capital Raising (Pre-IPO)

Looking to list on the ASX in the second quarter of 2010
For Sophisticated Investors Only



COMPANY OVERVIEW

- Minomic Pty Ltd (“MPL”) was established in 2002 by Dr Brad Walsh with a core business focus on the discovery of protein biomarkers. Dr Walsh and his team developed a technology platform to aid biomarker discovery and have expertise in the analysis of proteins from blood, urine and tears.
- Minomic International Ltd (“Minomic”) was established in 2007, as the company to house the Intellectual Property (“IP”) and commercialise late stage biotechnology development projects undertaken by MPL. In late 2009 Minomic acquired the majority of the assets of MPL, which principally consisted of staff, research and laboratory equipment.
- Minomic’s first flagship commercialisation project is focused on developing a monoclonal antibody-based diagnostic test for Prostate Cancer.
- With the ability to identify and test reliably for biomarkers of diseases such as cancer and diabetes, Minomic will enter a niche and growing market with few rivals. Hopefully the technology will provide major opportunities for rapid product range extension in diseases where traditional tests are limited or inadequate. Proteomics is revolutionising protein molecular diagnostics through the discovery of protein biomarkers that may be developed into highly predictive diagnostic tests. Minomic is at the forefront of this arena. Ultimately it is envisaged that these tests will provide improved patient care as well as providing pharmacoproteomic services that lead to improved drug toxicology, efficacy and diagnostic assays.
- Minomic has an impressive board of directors and scientific team, ensuring that the company is well equipped for global expansion and future development projects when the time arises.

PRE-IPO OFFER SUMMARY

Key Dates

Opening Date for Applications 4th January 2010

Offer Statistics

Offer Price	\$0.15 per ordinary Share	
No. of Shares on Issue @ 04/01/10	51,920,571	
	Min	Max
Shares Offered	1,700,000	13,333,334
Gross Proceeds of the Offer	\$255,000	\$2,000,000
No. of Shares on Issue post Offer	53,620,571	65,253,905
Market Capitalisation ¹	\$8,043,086	\$9,788,086

1. Calculated at Offer Price

PURPOSE OF OFFER & USE OF FUNDS

The subscription proceeds of the Shares to be issued under this pre-IPO capital raising will be used to:

- Provide for the continuing product development, including scientific research staff, laboratory, marketing and corporate administration costs (general working capital);
- Provide for the data collection, development and commercialisation to support prototype Diagnostic Test kits;
- Provide for operating expenses including the costs associated with the capital raising generally;
- Prepare for the Company’s ASX listing in about the second quarter of 2010;

SCIENCE OVERVIEW

- Minomic owns or has licenses to 100% of the Intellectual Property relevant to the prospective development of a monoclonal antibody-based diagnostic test for prostate cancer.
- With continued effort, based on progress to date, we believe that the Company will develop a prostate diagnostic test to the stage of regulatory evaluation in 2010.
- The potential test is based on a mouse monoclonal antibody (MAB) coded BLCA-38, which Minomic is able to use under the Materials Transfer Agreement with the South Eastern Sydney Illawarra Area Health Service.
- There are two significant features of Minomic’s work:
 1. The MAB BLCA-38 has shown utility for detecting the presence of bladder cancer cells in the urine of patients with this disease. It has also been shown that BLCA-38 binds to a protein on the surface of prostate cancer cells. When this information is coupled with the fact that there is published evidence that prostate cancer cells are present in urine it is likely that BLCA-38 will bind to prostate cancer in urine samples as it does in bladder cancer. The aim of this work is to use a panel of urines collected to test the efficacy of this novel approach.
 2. It will allow a test to determine if the protein is present in urine independent of the cancer cells, as well as a test to see whether the protein is present in serum.
- Minomic’s highly regarded Scientific Advisory Panel was formed in November 2009. Its mission is to:
 - Provide critical appraisal of scientific processes and achievements;
 - Offer strategic scientific direction to assist in the company’s future endeavors;
 - Ensure rigorous and ongoing challenge of the research programs;
 - Examine continued viability of projects against milestones;
 - Assess alternative approaches to projects existing and new;
 - Assess project competitiveness and alignment with company focus.



Minomic International Ltd
Up to \$2M Equity Capital Raising (Pre-IPO)
Looking to list on the ASX in the second quarter of 2010
For Sophisticated Investors Only



KEY INVESTMENT HIGHLIGHTS

- Successful completion of Minomic's trial process raises a significant commercial opportunity for the Company, particularly in view of its existing small capital base and worldwide market potential of the test kits.
- If Minomic's testing process establishes that BLCA38 has good sensitivity and specificity for detecting prostate cancer in urine, this will provide the Company with a significant commercial opportunity.
- Minomic's well advanced ability to identify and reliably test for biomarkers of diseases such as cancer is situated in a growing market. The science behind Minomic shows promise for major opportunities for rapid product range extension in diseases where traditional tests are limited or inadequate.
- Successful commercialisation of a prostate cancer test will allow Minomic to provide continuous funding for ongoing research and pipeline projects such as their Type 2 diabetes diagnostic test, funding growth for all commercial facets of the business, including acquisition of complimentary assets; and outstanding returns to all of Minomic's stakeholders.
- Recently the Company's scientists made an important breakthrough in Minomic's Prostate Cancer research revealing they have located the molecule from the prostate cancer cells to which BLCA-38 binds. This is a key milestone in the development of a diagnostic assay test for Prostate Cancer that has potential to be used in pathology labs worldwide.

MANAGEMENT TEAM

The Board of Directors represents a strong team with both depth and breadth of experience relevant to this venture. They share a commitment to ensuring high standards of corporate governance are implemented and maintained.

Dr Brad Walsh - PhD, B.Sc (Hons)

Chairman of Board

- Dr Walsh has 25 years experience in the biotechnology business and has enjoyed a successful career commercialising immunoassay kits and proteomics technologies and consumables as well as bioinformatics software. His products are being sold and supplied by major US corporations such as Waters and Bio-Rad.
- Before founding Minomic he was general manager of a not-for-profit public entity called the Australian Proteome Analysis Facility. This was a multi-million dollar facility established in 1995 by the Federal Government. Prior to this he led research groups in public institutions such as CSIRO, universities and hospitals.
- With his background and having successfully guided Minomic and MPL through six of the most turbulent years in biotech, both industry and government have eagerly sought his opinion as a thought leader and technologist. He has won prizes for the products being developed by the Company and was responsible for putting MPL on the 2006 business review weekly upstarts list of 200 fastest growing start-up companies.

Mr David Burdis - B.Bus

Non-Executive Director

- Mr Burdis is a qualified accountant and has worked in the chemical, telecommunications and financial services industries. He has held various senior/board positions, for both listed and unlisted companies, in Australia, the United Kingdom and Hong Kong including GFA International Limited, Swire Blanch Limited and OAMPS Limited. During his career he has been regularly involved in corporate acquisitions, divestitures and restructuring.
- Mr Burdis is the controlling shareholder of Qualita Management Pty Limited, a company providing outsourced management services to leading professional firms, including Ernst & Young and McGrath Nicol and Government.

Mr Robert Porter

Managing Director

- Mr. Porter has a specialist background in international reinsurance and financial services. He has worked as chief executive officer, trustee and managing director for a number of listed and unlisted companies in Australia and the United Kingdom. His diverse experience has been gained in companies such as Hannan Porter Reinsurance Limited, London Insurance Market Investment Trust plc, Sedgwick plc, Robert Fleming Insurance Brokers Limited, OAMPS Limited, and Biometrics Limited.
- Mr Porter has over many years been responsible for managing listed corporate assets in Australia, the United Kingdom, the United States of America and Bermuda. He was an underwriting member of Lloyd's of London for 17 years until 2003 and has a strong and successful background in company development, rehabilitation, risk management and administration.
- Current members of the Scientific Advisory Panel are:
 - **Dr Peter French**
 - **Professor Mark Willcox**
 - **Professor Pam Russell**
 - **Associate Professor Stuart Cordwell**
 - **Dr Paul Cozzi**

CONTACT DETAILS

Novus Capital Ltd

Level 8, 330 Collins St
Melbourne, VIC 3000
T: +61 3 8602 1710
F: +61 3 8602 1777

www.novuscapital.com.au

Nick Kapes

T: +61 3 8602 1714
M: 0438 354 443

Nick.Kapes@novuscapital.com.au

Ben Yeo

T: +61 3 8602 1713
M: 0403 351 836

Ben.Yeo@novuscapital.com.au

An Offer Information Statement ("OIS"), registered with ASIC, is also available upon request.